Latest Conference Articles

September 28th 2020, 10:47pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

September 28th 2020, 10:18pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

September 28th 2020, 9:59pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

September 28th 2020, 9:58pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

September 28th 2020, 9:30pm

Dana-Farber Cancer Institute

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

September 26th 2020, 4:00pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Efforts to leverage targeted therapy and immunotherapy, which have been approved modalities in advanced non–small cell lung cancer, are leading to improved survival in patients with advanced and earlier-stage disease.

September 26th 2020, 2:07pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Andre Goy, MD, MS, discusses updates in precision medicine. 

September 26th 2020, 1:30pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Natalie I. U. Vokes, MD, discusses the rise of predictive genomic biomarkers in oncology.

September 26th 2020, 1:00pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.

September 25th 2020, 9:25pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.

September 25th 2020, 6:17pm

ESMO Congress

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

September 24th 2020, 10:30pm

ESMO Congress

Andrew B. Nixon, PhD, ​MBA, discusses the role of microsatellite instability in cancer.

September 24th 2020, 10:26pm

ESMO Congress

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

September 24th 2020, 10:24pm

ESMO Congress

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

September 23rd 2020, 11:46pm

ESMO Congress

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

September 23rd 2020, 5:30pm

Continuous administration of the novel tubulin inhibitor VERU-111 proved to be safe and demonstrated antitumor activity, evidenced by prostate-specific antigen reductions, objective tumor responses, and durable activity, in men with previously treated metastatic castration-resistant prostate cancer.

September 21st 2020, 11:47pm

ESMO Congress

Ronan J. Kelly, MD, MBA, discusses the rationale to conduct the phase 3 CheckMate-577 study in esophageal or gastroesophageal junction cancer.

September 21st 2020, 11:45pm

ESMO Congress

The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

September 21st 2020, 11:43pm

ESMO Congress

Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.

September 21st 2020, 11:40pm

ESMO Congress

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.